NCT06257329 Patients With Severe Acute Exacerbation of COPD Ans Admitted in ICU Register.
| NCT ID | NCT06257329 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Alexis FERRE |
| Condition | COPD Exacerbation |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2022-10-01 |
| Primary Completion | 2027-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2022-10-01 with a primary completion date of 2027-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of this prospective observational study is to describe the epidemiological, clinical and biological characteristics of admitted patients in ICU for severe acute exacerbation of COPD, to assess the different therapeutics used, to evaluate the prognosis of patients with short, medium and long term ( 1 year) and the various factors associated with survival in ICU
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 40 years old 2. COPD documented or strongly suspected * Chronic respiratory symptoms (dyspnoea, cough and/or sputum) * Exposure to a known risk factor for COPD (such as tobacco smoke) * If available, respiratory function tests showing non- or partially reversible obstructive syndrom (post-bronchodilator ratio FEV1/CV \< 0.7) 3. Severe acute exacerbation, defined as a worsening of the patient's usual respiratory symptoms with signs of acute respiratory distress (polypnoea ≥ 30 cycles.min-1 or use of accessory respiratory muscles) and/or hypercapnic acidosis (with PaCO2 ≥ 45 mmHg and pH ≤ 7.35) 4. Admission to an ICU, a step-up unit or a respiratory care unit Exclusion Criteria: 1. Known asthma (according to the criteria of the international "Global initiative for asthma" guidelines) 2. Patient refusal to participate (information note, application for non-opposition)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06257329 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, studying COPD Exacerbation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06257329 currently recruiting?
Yes, NCT06257329 is actively recruiting participants. Contact the research team at aferre@ght78sud.fr for enrollment information.
Where is the NCT06257329 trial being conducted?
This trial is being conducted at Le Chesnay, France, Le Mans, France.
Who is sponsoring the NCT06257329 clinical trial?
NCT06257329 is sponsored by Alexis FERRE. The trial plans to enroll 2,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.